Rosa & Co. to Present Research Results at the 2018 American Conference on Pharmacometrics

Rosa & Co. LLC, an organization known worldwide for its PhysioPD™ Research Platforms, announced today that it will present posters with Takeda Pharmaceutical Company Ltd, and Boehringer Ingelheim GmbH at the Ninth American Conference on Pharmacometrics (ACoP9) in San Diego, California, October 7–10, 2018. The poster presentations will describe research in a range of therapeutic areas, including immuno-oncology, neurology, and respiratory diseases: On Monday Oct 8, in the morning, the research poster with Boehringer Ingelheim will be presented: "Development of the Respiratory PhysioPD™ Platform, a Quantitative Systems Pharmacology (QSP) Model, to Investigate Biological Mechanisms Underlying Bronchoconstriction". On Tuesday, Oct 9, in the morning, Rosa will present: "Evaluation of the Efficacy of a CD122 Biased Agonist for Treatment of Melanoma as a Monotherapy and in Combination with PD-1 Inhibition Using a Mechanistic Physiological Model". On Wednesday Oct 10, in the afternoon, the poster with Takeda will be presented: "Quantitative Systems Pharmacology Model to Quantify Benefits of DAO Inhibition in Schizophrenia". “When working with clients, we focus on giving them the tools to test hypotheses to make informed decisions about the disease pathophysiology, mechanism of action of the candidate drugs, and factors responsible for variability in the patient response,” said Rosa Founder, Chairman, and CEO Ron Beaver, PhD. “Using QSP and our PhysioPD™ Research Platform, we surface insights which help biopharma organizations to focus on most promising aspects of the drug efficacy and patient response.”The posters will be available at after the start of the ACoP9 meeting.